Docking analysis and multidimensional hybrid QSAR model of 1,4-benzodiazepine-2,5-diones as HDM2 antagonists

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 3, 2012, Pages 807-830

  Dai, Yujie ^a   Chen, Nan ^a   Wang, Qiang ^a   Zheng, Heng ^b   Zhang, Xiuli ^c   Jia, Shiru ^a   Dong, Lilong ^d   Feng, Dacheng ^e  

^a TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c University of Missouri   (United States)

^d HEBEI MEDICAL UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

Author keywords

1,4 benzodiazepine 2,5 diones; CDOCKER; Docking; p53 HDM2 interaction; QSAR

Indexed keywords

1,4 BENZODIAZEPINE 2,5 DIONE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; LIGASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; DRUG ACTIVITY; DRUG PROTEIN BINDING; ENZYME INHIBITION; GENETIC ANALYSIS; IC 50; MOLECULAR DOCKING; PHYSICAL CHEMISTRY; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84865166278     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Vogelstein B and Kinzler KW. p53 Function and dysfunction. Cell (1992) 70: 523-526.
2. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. (1996) 88: 1442-1455.
3. Kubbutat MH and Vousden KH. Keeping an old friend under control: regulation of p53 stability. Mol. Med. Today (1998) 4: 250-256.
4. Leonard K, Marugan JJ, Raboisson P, Calvo R, Gushue JM, Koblish HK, Lattanze J, Zhao S, Cummings MD, Player MR, Maroney AC and Lu T. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorg. Med Chem. Lett. (2006) 16: 3463-3468.
5. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer (2003) 3: 102-109.
6. Blaydes JP and Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene (1998) 16: 3317-3322.
7. Chène P, Fuchs J, Bohn J, GarcIa-EcheverrIa C, Furet P and Fabbro D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. (2000) 299: 245-253.
8. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF and Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in-vivo. Curr. Biol. (1997) 7: 860-869.
9. Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, Debussche L and Wasylyk B. cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene (1999) 18: 1921-1934.
10. Wang H, Nan L, Yu D, Agrawal S and Zhang R. oligonucleotides as a novel therapeutic approach to human breast cancer: In-vitro and in-vivo activities and mechanisms. Clin. Cancer Res. (2001) 7: 3613-3624.
11. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ and Bone RF. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. (2005) 48: 909-912.
12. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Mühlhahn P, Schumacher R, Hesse F, Kaluza B, Voelter W, Engh RA and Holak TA. Chalcone derivatives antagonize interactions between the human oncoprotein. MDM2 and p53. Biochem. (2000) 40: 336-344.
13. Zhao J, Wang M, Chen J, Luo A, Wang X, Wu M, Yin D and Liu Z. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Let. (2002) 183: 69-77.
14. Galatin PS and Abraham DJ. p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. (2004) 47: 4163-4165.
15. Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Gupta V, Lattanze J, Ramachandren K, Carver TE, Petrella EC, Cummings MD, Maguire D, Grasberger BL and Lu T. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: Discovery and SAR. Bioorg. Med. Chem. Lett. (2005) 15: 765-770.
16. Agrafiotis DK. Stochastic algorithms for maximizing molecular diversity. J. Chem. Inf. Comput. Sci. (1997) 37: 841-851.
17. Rassokhin DN and Agrafiotis DK. Kolmogorov-Smirnov statistic and its application in library design. J. Mol. Graphics Model (2000) 18: 368-382.
18. Agrafiotis DK, Lobanov VS and Salemme FR. Combinatorial informatics in the post-genomics era. Nat. Rev. Drug Discov. (2002) 1: 337-346.
19. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, Carver T, Asel E, Springer BA, Lane P and Salemme FR. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. (2001) 6: 429-440.
20. Cummings MD, Schubert C, Parks DJ, Calvo RR, LaFrance LV, Lattanze J, Milkiewicz KL and Lu T. Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chem. Biol. Drug Des. (2006) 67: 201-205.
21. Wang F, Li Y, Ma Z, Wang X and Wang Y. Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics. J. Mol. Model. (2011) DOI: 10.1007/s00894-011-1041-4.
22. Galatin PS and Abraham DJ. The tumor suppressor p53: from structures to drug discovery. Proteins (2001) 45: 169-175.
23. Xu H and Agrafiotis DK. Retrospect and prospect of virtual screening in drug lead discovery. Curr. Topics Med. Chem. (2002) 2: 1305-1320.
24. Discovery Studio 2.1. Accelrys Inc, San Diego (2007).
25. MOE Molecular Operating Environment, Chemical Computing Group Inc, Montreal (2008).
26. SYBYL 8.0, Tripos International, Missouri (2008).
27. Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, Palyulin VA, Radchenko EV, Zefirov NS, Makarenko AS, Tanchuk VY and Prokopenko VV. Virtual computational chemistry laboratory-design and description. J. Comput. Aid Mol. Des. (2005) 19: 453-463.
28. Roy P and Roy K. Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors. J. Mol. Model. (2010) 16: 1597-1616.
29. Dai Y, Wang Q, Zhang X, Jia S, Zheng H, Feng D and Yu P. Molecular docking and QSAR study on steroidal compounds as aromatase inhibitors. Eur. J. Med. Chem. (2010) 45: 5612-5620.
30. Wallace AC, Roman AL and Thornton Janet M. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. (1995) 8: 127-134.
31. Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugan JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC and Lu T. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg. Med. Chem. Lett. (2006) 16: 3310-3314.
32. Marugan JJ, Leonard K, Raboisson P, Gushue JM, Calvo R, Koblish HK, Lattanze J, Zhao S, Cummings MD, Player MR, Schubert C, Maroney AC and Lu T. Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists. Bioorg. Med. Chem. Lett. (2006) 16: 3115-3120.
33. Wu G, Robertson DH, Brooks CL and Vieth M. Study of CDOCKER-a CHARMm-based MD docking algorithm. J. Comput. Chem. (2003) 24: 1549-1562.
34. ChemBioOffice Ultra Version 11.0, CambridgeSoft Inc, Cambridge (2008).
35. Kirkpatrick S, Gelatt CD and Vecchi MP. Optimization by simulated annealing. Science (1983) 220: 671-680.
36. Kirkpatrick S. Optimization by Simulated Annealing: Quantitative Studies. J. Stat. Phy. (1984) 34: 975-986.
37. So SS and Karplus M. Optimization in quantitative structure-activity. relationship: an application of genetic neural networks. J. Med. Chem. (1996) 39: 1521-1530.
38. Caballero J, Fernández L, Garriga M, Abreu JI, Collina S and Fernández M. Proteometric study of ghrelin receptor function variations upon mutations using amino acid sequence autocorrelation vectors and genetic algorithm-based least square support vector machines. J. Mol. Graphics Model (2007) 26: 166-178.
39. Materials Studio Modeling 4.0. Accelrys Software Inc, San Diego (2007).
40. Friedman JH. Multivariate adaptive regression splines. Ann. Statistics (1991) 19: 1-67.
41. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. (2004) 25: 1605-1612.
42. Dezi C, Carotti A, Magnani M, Baroni M, Padova A, Cruciani G, Macchiarulo A and Pellicciari R. Molecular interaction fields and 3d-qsar studies of p53-mdm2 inhibitors suggest additional features of ligand-target interaction. J. Chem. Inf. Model (2010) 50: 1451-1465.